Abstracts Archive - Page 1194 of 2607 - ACR Meeting Abstracts

Abstract Number: 113 • 2018 ACR/ARHP Annual Meeting
Epigenetic Changes in Dermal Fibroblasts By Inhibition of DOT1L Affect Cell Proliferation and Cell Cycle, but Have No Direct Effects on Collagen Deposition in in Vitro and In Vivo models of Fibrosis
Nathalie Berghen^1,2, Jonathan Cremer³, Ellen de Langhe^1,2 and Rik Lories^1,2, ¹Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ²Rheumatology, UZ Leuven, Leuven, Belgium, ³Translational Research in GastroIntestinal Disorders, KU Leuven, Leuven, Belgium
Background/Purpose: Fibrosis is a key feature of systemic sclerosis, a devastating disease that is not well understood. The role of epigenetic factors in the pathophysiology…
Abstract Number: 114 • 2018 ACR/ARHP Annual Meeting
Antifibrotic Regulation By Response Gene to Complement 32 Protein
Sergei Atamas, Violeta Rus, Virginia Lockatell, Horea Rus and Irina Luzina, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Pulmonary fibrosis is a serious problem in patients with scleroderma lung disease (SLD). Better therapies for pulmonary fibrosis are urgently needed. Identification of new…
Abstract Number: 115 • 2018 ACR/ARHP Annual Meeting
CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients
Maurizio Cutolo¹, Paola Montagna², Stefano Soldano¹, Amelia Chiara Trombetta³, Barbara Ruaro⁴, Paola Contini⁵, Sabrina Paolino⁶, Carmen Pizzorni⁴, Elisa Alessandri⁴, Massimo Patanè¹, Alberto Sulli⁴, Stefano Scabini⁷, Emanuela Stratta⁷ and Renata Brizzolara¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital, Genova, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genova, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁵Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino, Genova, Italy, Genova, Italy, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, ⁷Oncologic Surgery, Department of Surgery, IRCCS Polyclinic San Martino, Genova, Italy, Genoa, Italy
Background/Purpose: CTLA4-Ig interacts with the cell surface costimulatory molecule CD86 and can downregulate the target cell activation [1]. Circulating fibrocytes (CFs) express markers of both…
Abstract Number: 116 • 2018 ACR/ARHP Annual Meeting
Identifying Matricellular Protein CYR61 As a Potential Anti-Fibrotic and Pro-Angiogenic Mediator in Scleroderma
Pei-Suen Tsou¹, Dinesh Khanna² and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Scleroderma Program, Ann Arbor, MI
Background/Purpose: Vascular abnormalities represent a fundamental event in the pathogenesis of scleroderma (SSc) in that endothelial cell (EC) damage triggers a self-fueling process ending in…
Abstract Number: 117 • 2018 ACR/ARHP Annual Meeting
Hypomorphic A20 Expression Modulates Fibrosis Susceptibility: Implications for Systemic Sclerosis?
Swati Bhattacharyya¹, Wenxia Wang², Brian M. Jeong², Hiam Abdala-Valencia³, Roberta Goncalves Marangoni¹, Sergejs Berdnikovs Ph.D.⁴ and John Varga¹, ¹Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Medicine, Northwestern University, Chicago, IL
Background/Purpose: Mutiple organ fibrosis, a hallmark of systemic sclerosis (SSc), remains poorly understood. Recent GWAS have uncovered consistent genetic linkage between TNFAIP3, encoding the ubiquitin-editing…
Abstract Number: 118 • 2018 ACR/ARHP Annual Meeting
Pharmacological Inhibition of JAK/STAT Signaling By Tofacitinib Prevents Experimental Organ Fibrosis: Novel Therapy for Systemic Sclerosis
Swati Bhattacharyya¹, Wenxia Wang², Jun Wei³ and John Varga¹, ¹Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Northwestern University, chicago, IL
Background/Purpose: Synchronous fibrosis in systemic sclerosis (SSc) leads to failure of the skin, lungs and other organs, and has no effective treatments. Myofibroblast activation underlies…
Abstract Number: 119 • 2018 ACR/ARHP Annual Meeting
Targeting Dysregulated CD38/NAD+ Homeostasis Mitigates Multiple Organ Fibrosis
Bo Shi¹, Wenxia Wang², Swati Bhattacharyya¹, Benjamin Korman³, Roberta Goncalves Marangoni¹, David Camp⁴, Paul Cheresh⁵, Guilherme de Oliveira⁶, Eduardo Chini⁷ and John Varga¹, ¹Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Department of Rheumatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Division of Pulmonary and Critical Care, Northwestern University, Chicago, IL, ⁵Northwestern University, CHICAGO, IL, ⁶Mayo Clinic of Medicine, Rochester, MN, ⁷Kogod Center on Aging, Mayo Clinic, Rochester, MN
Background/Purpose: Persistent myofibroblast activation underlies unresolving multi-organ fibrosis in systemic sclerosis (SSc). We had shown that fibrosis is associated with reduced expression of NAD-dependent sirtuins…
Abstract Number: 120 • 2018 ACR/ARHP Annual Meeting
An Orally Available Highly Selective 5-Hydroxytryptamine 2B Receptor Antagonist Ameliorating Pulmonary and Dermal Fibrosis in Preclinical Models of Systemic Sclerosis
Christina Wenglén¹, Helena Arozenius², Lars Pettersson² and Gunilla Ekström¹, ¹R&D, AnaMar AB, Lund, Sweden, ²AnaMar AB, Lund, Sweden
Background/Purpose: Serotonin or 5-hydroxytryptamine (5-HT) is well known as a stimulator of tissue fibrosis and a significant role of peripheral 5-HT2B receptors in fibrosis has…
Abstract Number: 121 • 2018 ACR/ARHP Annual Meeting
Inhibition of Nuclear Receptor Coactivator 3 Attenuates Fibrosis in Murine Models of Systemic Sclerosis
Sebastian Poetter¹, Clara Dees¹, Christina Bergmann¹, Andreas Ramming¹, Oliver Distler², Georg Schett³ and Jörg Distler¹, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, 8952 Schlieren, Switzerland, ³Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Uncontrolled activation of fibroblasts releasing large amounts of extracellular matrix proteins is a key feature of systemic sclerosis (SSc). The nuclear receptor coactivators (NCOA)…
Abstract Number: 122 • 2018 ACR/ARHP Annual Meeting
Metformin Inhibited the Development of Bleomycin-Induced Murine Scleroderma Via Restoring the Balance between Regulatory and Effector T Cells and Suppressing Spleen Germinal Center Formation
Yanlin Wang¹, Zhaojun Liang², Xiangcong Zhao¹, Chong Gao³ and Jing Luo⁴, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Division of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China, Taiyuan, China, ³Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ⁴the Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Scleroderma is a multisystem connective tissue disease characterized by extensive tissue fibrosis and its three prominent cardinal features are vasculopathy, excessive collagen deposition and immunological abnormalities. Metformin (MET)…
Abstract Number: 123 • 2018 ACR/ARHP Annual Meeting
Non-Hematopoietic Derived TNF Drives Pulmonary Vasculopathy: A New Model of CTD-Associated Pulmonary Hypertension
Richard Bell¹, Maria de la Luz Garcia-Hernandez², Javier Rangel-Moreno³, Christopher T. Ritchlin², Homaira Rahimi⁴ and Edward Schwarz⁵, ¹Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ²Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ³Division of Allergy, Immunology and Rheumatology and Center for Musculoskeletal Research School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY
Background/Purpose: Cardiopulmonary disease is a severe comorbidity in many connective tissue diseases (CTD). Rheumatoid arthritis, systemic sclerosis, and systemic lupus patients are all at increased…
Abstract Number: 124 • 2018 ACR/ARHP Annual Meeting
M10, a Small Fragment of the Hepatocyte Growth Factor Receptor, Attenuates Fibrotic Changes in a Murine Model of Scleroderma Lung Disease and in Human Lung Fibroblasts
Tanjina Akter¹, Ilia Atanelishvili¹, Atsushi Noguchi², Galina S. Bogatkevich¹ and Rick Silver³, ¹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology, Endocrinology and Nephrology,, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Rheumatology, Medical University of SC, Charleston, SC
Background/Purpose: Interstitial lung disease (ILD) is the major cause of mortality among scleroderma (systemic sclerosis, SSc) patients. Extracellular matrix (ECM) deposition is a hallmark of…
Abstract Number: 125 • 2018 ACR/ARHP Annual Meeting
Monocyte Transcriptome Delineates SSc Patients with Functionally Distinct Patterns of Gene Dysregulation That Persist through Differentiation
Julia L.M. Dunn¹, Philip J. Homan², Salina Dominguez¹, Carla M. Cuda¹, Kathleen Aren³, Mary A. Carns^3,4, Tracy M. Frech⁵, Dinesh Khanna⁶, Shervin Assassi⁷, Harris Perlman¹, Monique Hinchcliff¹ and Deborah R. Winter¹, ¹Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: The etiology and pathogenesis of SSc are poorly understood; however, an increasing body of evidence supports an early inflammatory phase that precedes, and may…
Abstract Number: 126 • 2018 ACR/ARHP Annual Meeting
Direct Interaction between Autoreactive B Cells and Endothelial Colony Forming Cells Induces Cytokine Production from B Cells through B Cell Receptor and IL-6-JAK2-STAT3 Signaling Pathway, Suppressing Proliferation of Endothelial Colony Forming Cells in Systemic Sclerosis
Takemichi Fukasawa¹, Ayumi Yoshizaki¹, Satoshi Ebata¹, Kouki Nakamura¹, Yoshihide Asano¹, Yutaka Kazoe², Kazuma Mawatari², Takehiko Kitamori² and Shinichi Sato¹, ¹Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Applied Chemistry, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disorder that is characterized by fibrosis and vascular damage in the skin and other visceral organs, with…
Abstract Number: 127 • 2018 ACR/ARHP Annual Meeting
MiR-3606-3p Inhibits Systemic Sclerosis through Targeting TGF-β Receptor II
Xiangguang Shi¹, Qingmei Liu², Wenzhen Tu³, Xueqian Mei¹, Li Jin⁴, Wenyu Wu⁵ and Jiucun Wang⁴, ¹State Key Laboratory of Genetic Engineering, Department of Anthropology and Human Genetics, School of Life Sciences, Fudan University, Shanghai, China, ²State Key Laboratory of Genetic Engineering and Ministry of Education Key Laboratory of Contemporary Anthropology, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, Chile, ³Medicine, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shang hai, China, ⁴State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China, ⁵Department of Dermatology, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China
Background/Purpose: Though transforming growth factor-b (TGF-b) plays a fundamental role in the pathogenesis of SSc, the mechanism by which TGF-b signaling acts in SSc remains…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].